Address: No. 35, Simiao Road, Daxing Biomedical Industrial Base, Zhongguancun Science Park, Daxing District, Beijing
Copyright: Beijing Minhai Biological Technology Co., Ltd. Beijing ICP 10007676 Powered by www.300.cn Beijing Beijing Public Security No. 110115000037 Internet Drug Information Service Qualification Certificate (Beijing) Non-operating 20150173
Administrative Office: 010-59613600
Supplier consultation: 010-59613585
Medical support: 010-59613669
Pneumonia "nemesis": Minhai Biological 23-valent pneumococcal vaccine successfully launched
On August 13, 2019, the 23-valent pneumococcal polysaccharide vaccine produced by Beijing Minhai Biological Technology Co., Ltd. (hereinafter referred to as Minhai Biological) successfully passed the review of the State Drug Administration and successfully obtained the biological product batch issuance certificate. The product was sent to the local market one after another through procedures such as the provincial vaccine bidding and procurement platform.
Minhai Biological 23-valent pneumococcal polysaccharide vaccine can produce 10 million doses per year and is currently the only dual-dose 23-valent pneumococcal polysaccharide vaccine used to prevent pneumonia, meningitis, otitis media and bacteremia caused by 23 pneumococcal serotype Diseases, such as diseases, suitable for susceptible people 2 years old and above, especially the elderly, people with normal immune function but chronic diseases, people with low immune function, asymptomatic and symptomatic HIV infection, patients with cerebrospinal fluid leakage, in the infection Key populations such as pneumococcus or intensive occupants or staff in high-risk environments with their complications.
At present, there are two main types of pneumococcal vaccines on the domestic market: 13-valent pneumococcal polysaccharide conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Among them, the 13-valent pneumococcal polysaccharide conjugate vaccine is mainly used for immunization of infants and children under 2 years old.
The Chinese Preventive Medicine Association pointed out in the "Guidelines for the Application of Vaccines Related to Pneumococcal Diseases": "S. pneumoniae is an important pathogen leading to the morbidity and mortality of children and the elderly in China. Vaccines are an important measure to prevent pneumococcal diseases. "
The 23-valent pneumococcal polysaccharide vaccine of Minhai Biological Co., Ltd., Weimin Feile, was granted the certificate of approval this time, marking the formal entry of the vaccine into the market and providing protection options for eligible recipients.